Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fulvestrant in PIK3CA mutation/HR-positive/HER2-negative Breast Cancer: NCT07748208 Clinical Landscape Report 2026
18 September 2026
NCT07748208 clinical landscape for PIK3CA mutation/HR-positive/HER2-negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Ubidecarenone in Noninsulin-Dependent Diabetes Mellitus With Deafness: NCT07748130 Clinical Landscape Report 2026
18 September 2026
NCT07748130 clinical landscape for Noninsulin-Dependent Diabetes Mellitus With Deafness: endpoints, sponsor, phase, geography, readouts, asset context and de…
9 min read
Cemiplimab-RWLC in Resectable Lung Non-Small Cell Carcinoma: NCT07746388 Clinical Landscape Report 2026
18 September 2026
NCT07746388 clinical landscape for Resectable Lung Non-Small Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Icodec Insulin in Diabetes Mellitus, Type 2: NCT07747402 Clinical Landscape Report 2026
18 September 2026
NCT07747402 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TQF3250 in Diabetes Mellitus, Type 2: NCT07747857 Clinical Landscape Report 2026
18 September 2026
NCT07747857 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab/Hyaluronidase in Rectal Adenocarcinoma: NCT07750158 Clinical Landscape Report 2026
18 September 2026
NCT07750158 clinical landscape for Rectal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DA-302168S in Diabetes Mellitus, Type 2: NCT07755150 Clinical Landscape Report 2026
18 September 2026
NCT07755150 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Metastatic malignant neoplasm to nasopharynx: NCT07756190 Clinical Landscape Report 2026
18 September 2026
NCT07756190 clinical landscape for Metastatic malignant neoplasm to nasopharynx: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Ipilimumab N01 in MSI-H/dMMR Rectal Cancer: NCT07750951 Clinical Landscape Report 2026
18 September 2026
NCT07750951 clinical landscape for MSI-H/dMMR Rectal Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bevacizumab biosimilar(Qilu Pharmaceutical Co., Ltd.) in Advanced Colorectal Adenocarcinoma: NCT07750041 Clinical Landscape Report 2026
18 September 2026
NCT07750041 clinical landscape for Advanced Colorectal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Survodutide in Diabetes Mellitus, Type 2: NCT07754461 Clinical Landscape Report 2026
18 September 2026
NCT07754461 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SYS-6010 in Squamous cell carcinoma of head and neck metastatic: NCT07758621 Clinical Landscape Report 2026
18 September 2026
NCT07758621 clinical landscape for Squamous cell carcinoma of head and neck metastatic: endpoints, sponsor, phase, geography, readouts, asset context and dev…